Abbott Laboratories (ABT) is overvalued and GE HealthCare Technologies Inc (GEHC) is undervalued.
Against our estimates of intrinsic value, GEHC trades at the wider discount: a margin of safety of +29%, against -48% for ABT.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $70.00; the price of $103.69 is 48% above that value, and 78% of that value comes from beyond year five.
Leak Score 57/100 on 10 of 12 signals
Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $93.41; the price of $66.27 is 29% below that value, and 75% of that value comes from beyond year five.
Leak Score 63/100 on 5 of 12 signals
| Metric | ABT | GEHC |
|---|---|---|
| Verdict | Overvalued | Undervalued |
| Price | $103.69 | $66.27 |
| Intrinsic value | $70.00 | $93.41 |
| Margin of safety | -48% | +29% |
| Leak Score | 57/100 (10/12) | 63/100 (5/12) |
| Market cap | $179.4B | $29.9B |
| Revenue growth, 5 years | 5.1% | 3.7% |
| Operating margin | 16.4% | 13.7% |
| Net margin | 11.6% | 9.3% |
| Return on equity | 10.6% | 19.2% |
| Debt to equity | 0.64 | 0.96 |
| P/E | 33.5x | 15.2x |
| Forward P/E | 17.1x | 12.2x |
| P/B | 3.5x | 2.7x |
| Dividend yield | 2.5% | 0.2% |